EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.341
https://www.valueinhealthjournal.com/article/S1098-3015(23)03471-X/fulltext
Title :
EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03471-X&doi=10.1016/j.jval.2023.09.341
First page :
Section Title :
Open access? :
No
Section Order :
12365